|
|
|
|
|
|
|
|
 |
|
 |
|
| ABOUT THE SPEAKERS |
|
| This most comprehensive conference on Stem Cell will feature more than 20 renowned international speakers and 20 hours of in-depth programming in stem cell applications, developments & benefits. |
|
|
 |
| Prof.Mahendra S Rao. M.D., Ph. D |
| Head of Center for Regenerative Medicine.
NIH, Bethesda,USA
|
| Key Note address during the inaugural session
|
Dr. Rao is internationally renowned for his research involving human embryonic stem cells (hESCs) and other somatic stem cells. He has worked in the stem cell field for more than 20 years, with stints in academia, government and regulatory affairs and industry.
He received his M.D. from Bombay University in India and his Ph.D. in developmental neurobiology from the California Institute of Technology, Pasadena. Following postdoctoral training at Case Western Reserve University, Cleveland, he established his research laboratory in neural development at the University of Utah, Salt Lake City.
He next joined the National Institute on Aging as chief of the Neurosciences Section, where he studied neural progenitor cells and continued to explore his longstanding interest in their clinical potential. He then spent six years as the vice president of Regenerative Medicine at Life Technologies, Carlsbad, Calif. Most recently, he returned in August 2011 to the National Institutes of Health (NIH), as Director of the new NIH Center for Regenerative Medicine (NIH CRM). He co-founded Q Therapeutics, a neural stem cell company based in Salt Lake City.
He also served internationally on advisory boards for companies involved in stem cell processing and therapy, on committees including the U.S. Food and Drug Administration’s Cellular Tissue and Gene Therapies Advisory Committee chair, and as the California Institute of Regenerative Medicine and International Society for Stem Cell Research liaison to the International Society for Cellular Therapy.
|
|
|
|
 |
| Dr. Mohan C Vemuri, Ph.D |
| Director, R&D, Stem Cells, Life Technologies, USA |
Mohan Vemuri is currently the Director, Research and Development of Stem Cells and
Regenerative Medicine at Life Technologies. Dr. Vemuri has been with the company since 2006 in different R&D leadership roles and instrumental in stem cell based product development for human pluripotent (embryonic and iPSC) and adult stem cell expansion, differentiation in cGMP regulated
conditions for applied research and cell therapy . Dr. Vemuri has served as faculty and staff at Children’s Hospital of Philadelphia (University of Pennsylvania) and worked on engineering stem cells for enhanced self renewal, competitive engraftment and immune reconstitution utilizing novel
gene transfer technology with hematopoietic stem cells.
Dr. Vemuri was also responsible for designing stem cell based assays and lead drug discovery using cell culture systems to treat Parkinson’s disease in GLP settings at Thomas Jefferson University. Dr. Vemuri is a recipient of National Institutes of Health Fogarty Fellowship award and best investigator award and a citation for deriving hESC from the Association of Reproductive Medicine for the year 2005.
Dr. Vemuri has held scientific positions in University of Hyderabad, Thomas Jefferson University, and University College of Sciences in Philadelphia. Dr. Vemuri has authored over 50 publications in peer reviewed journals, and edited three books,1) Stem Cell Assays 2. Regulatory Networks in Stem Cells and 3., MSC Assays and Applications, by Springer/Humana Press.
Dr. Vemuri presently works and collaborates with different investigators towards the successful utilization of
stem cells in regenerative cell therapies in a regulatory compliant environment. |
|
|
|
|
 |
| Dr Stephen Minger, Ph.D |
| Global Head (R&D), GE Healthcare, UK |
Dr Stephen Minger was previously the Director of the Stem Cell Biology Laboratory and a Senior Lecturer in the new Wolfson Centre for Age Related Diseases at King's College London.
Dr Minger received his PhD in Pathology (Neurosciences) in 1992 from the Albert Einstein College of Medicine. From 1992-1994, he was a post-doctoral fellow at the University of California,
San Diego, where he first began to pursue research in neural stem cell biology. In 1995, Dr Minger was appointed an Assistant Professor in Neurology at The University of Kentucky Medical School.
He moved his stem cell research programme to Guy's Hospital in 1996 and was appointed a Lecturer in Biomolecular Sciences at King's College London in 1998.
Over the last 15 years, his research group has worked with a wide range of somatic stem cell populations, as well as mouse and human embryonic stem (ES) cells. In 2002, together with Dr Susan
Pickering and Professor Peter Braude, Dr Minger was awarded one of the first two licenses granted by the UK Human Fertilisation and Embryology Authority for the derivation of human ES cells.
His group subsequently generated the first human embryonic stem cell line in the UK and was one of the first groups to deposit this into the UK Stem Cell Bank. They have gone on to generate three new human
ES cell lines, including one that encodes the most common genetic mutation resulting in Cystic Fibrosis. In addition to the derivation of human ES cell lines, the Stem Cell Biology Laboratory is focused on the generation
of a number of therapeutically relevant human somatic stem cell populations from embryonic stem cells.
These include cardiac, vascular, retinal, and neural stem/progenitor cell populations, as well pancreatic ?-cells and oligodendrocyte progenitors. Dr Minger has established highly productive collaborations with a
number of specialist groups in many areas of clinical interest throughout the UK, and is one of the co-organisers of the London Regenerative Medicine Network, a grass-roots, research-led organisation designed to
stimulate clinical translation of cell- and genebased therapies within London. He is also the Senior Editor of Regenerative Medicine, a new journal launched in Jan 2006 by Future Medicines.
Dr Minger's research is supported by the UK Medical Research Council, The European Union, GlaxoSmithKline PLC, The Novartis Institute, The Oliver Bird Foundation, The Wellcome Trust, The UK Department of Trade and Industry,
The Huntington's Disease Association, The Charitable Foundation of Guy's and St Thomas' Hospitals, the BBSRC, and the EPSRC amongst others.
|
|
|
|
|
 |
| Dr. Maria Carolina Oliveira MD, PhD, |
| Hospital das Clinicas de Ribeirao Preto - USP
School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil |
|
|
|
|
|
 |
| Dr. Uma Lakshmipathy, M.D., Ph. D |
| Associate Director, R&D
Primary and Stem Cell Systems
Life Technologies,
CA, USA
|
Dr Uma Lakshmipathy has been involved in the field of stem cells for nearly a decade. Her doctoral degree in Molecular Biophysics and subsequent postdoctoral experience in DNA repair brought new perspective and led her to the area of stem cell research with focus on developing ex vivo gene repair systems.
As a junior faculty at the Stem Cell Institute, University of Minnesota, she identified efficient gene delivery methods into stem cells to
enable repair of adult stem cells from monogene disorders. She moved to Invitrogen, Life Technologies, in 2005 and was involved in the development of novel technology platforms for creating labeled stem cells. Her current research interests are regulation of stem cells maintenance, development of technologies for identification, characterization and differentiation of stem cells. |
|
|
|
|
 |
| Prof. Raghu Vemuganti, Ph. D |
| Associate Professor
Department of Neurological Surgery,
University of Wisconsin,
H4/334 Clinical Science Center,
600 Highland Avenue,
Madison WI 53792
|
Dr. Raghu Vemuganti obtained his PhD from the School of Life Sciences, University of Hyderabad, India in 1991. His thesis was on the significance of glutamatergic dysfunction following hepatic encephalopathy. Raghu spent 5 years at the University of Montreal as a post-doctoral fellow working on the molecular mechanisms of brain dysfunction in liver cirrhosis. Raghu joined University of Wisconsin as an Assistant Scientist in 1996 and elevated through the ranks to the position of Tenured Associate Professor in the Department of Neurological Surgery. The major focus of his lab is to decipher the molecular mechanisms of brain damage and plasticity following stroke and traumatic brain injury. Raghu published >115 peer-reviewed papers and presented his work at >150 National and International meetings.
His lab is supported by multiple grants from the National Institute of Health and the American Heart Association. Raghu serves as a chartered member of the NIH Grant Review Study Section BINP. He also serves on the NIH Stroke Program Review Group. |
|
|
|
|
 |
| Prof. Radhika Pochampally, Ph. D |
| Assistant Professor
Department of Pharmacology
Tulane Center for Stem Cell Research and Regenerative Medicine
New Orleans, LA, USA
|
Dr. Pochampally has a broad background in adult stem cells and cancer biology, with specific training and expertise in Mesenchymal stem cell, cancer stem cell, osteosarcoma biology.
She leads an academic research group interested in understanding the microRNA and other molecular regulatory mechanisms that play a role in the stromal supportive properties of Mesenchymal stem cells, with an eventual goal to generate small RNA based diagnostic markers and therapeutic targets for tumor stroma in breast and bone cancers.
Dr. Pochampally is an assistant professor at Tulane University Health Science Center, a member of Tulane Cancer Center and Tulane Center for Stem Cell and Regenerative Medicine.
She attended Louisiana State University Health Science Center in New Orleans , where she earned her Ph.D in 2000 with dissertation focused on p53 and MDM2 regulation. Mentor: Dr. Jiandong Chen.
Her post doctoral training was in the field of adult stem cell biology. Mentor: Dr. Darwin Prockop, a leading scientist in Mesenchymal Stem Cells
|
|
|
|
|
 |
| Dr. Ashok Khar, |
| Director,
Cell and Molecular Biology Res. CTD,
Apollo Hospitals,
Hyderabad
|
Dr.Ashok Khar had 25 years of research career at the Centre for Cell & Molecular Biology, Hyderabad in the area of tumour immunology and cell culture. He was also involved as Head of Research and Development at Shantha Biotechnics Ltd, in the development of vaccines, recombinant biotherapeutics and therapeutic monoclonal antibodies.
Dr. Khar is the fellow of the National Academy of Sciences, India and is recipient of several awards like the T.B.Patel Award in Cancer Research, NIH Physician’s Recognition Award of the American Medical Association, Indian Immunology Society Senior Scientist Award, Prof Y.T.Thathachari Award and M.G.Deo Award in Cancer Research. Dr.Khar has published ten invited reviews in addition to 140 scientific publications in peer reviewed international journals . Dr.Khar is presently the Director of Cell & Molecular Biology Research Centre at Apollo Health City where he is involved in the applications of stem cells in Research and Therapeutics.
|
|
|
|
|
 |
| Dr.Bruce Whitelaw, Ph. D |
Professor of Animal Biotechnology, Head of Division,
The Roslin Institute and Royal (Dick) School of Veterinary Studies,
Division of Developmental Biology,
University of Edinburgh Easter Bush Campus Midlothian EH25 9RG, Scotland UK
|
Bruce Whitelaw was awarded a BSc degree in Medical Microbiology from the University of Edinburgh in 1982 and obtained his Ph.D. in 1987 from the University of Glasgow. He is currently Head of Division at The Roslin Institute and Professor of Animal Biotechnology at the University of Edinburgh. Bruce is a recognised world expert on transgenic animals, holds 7 patents relating to GM animals and has published over 100 scientific papers relating to this topic. He has had roles with the OIE, HSE's ACGM, FERA, EFSA and is Editor-in-Chief of the journal Transgenic Research. Currently Bruce is Vice President Animal Biotechnology with NewVectys SAS, is a scientific advisor to ImmunoGenes AG and Recombinetics Inc, and sits on the jury for the Fundacion BBVA Frontiers of Knowledge Awards for Biomedicine.
|
|
|
|
|
 |
| Professor Sheila MacNeil, BSc, Ph. D |
| Professor of Tissue Engineering
The Kroto Research Institute
North Campus, University of Sheffield
Broad Lane, Sheffield, S3 7HQ
|
Sheila MacNeil is Professor of Tissue Engineering in the University of Sheffield . She leads a large multidisciplinary group focused on biomaterials and tissue engineering.
Her group focus on the development of tissue engineered skin and other epithelial tissues (oral mucosa, oesophagus, bladder, pelvic floor and cornea) and they have successfully developed tissue engineered skin products through to commercialisation (MySkin and Cryoskin) to benefit patients with severe burns and chronic wounds.
She works extensively with clinical colleagues in Burns, Dermatology and Urology and her research benefits from a strongly interdisciplinary approach with excellent biomaterials support from academic colleagues in Engineering Materials and Chemistry.
Recent tissue engineering challenges include development of scaffolds for repair of the female pelvic floor, development of biomaterials to deliver corneal cells to patients and development of hybrid biomaterials for cleft palate repair.
|
|
|
|
|
 |
| Dr. Hidenori Akutsu, MD.,Ph. D |
| National Center for Child Health and Development
National Medical Center for Children and Mothers
Research Institute
Tokyo, Japan
|
Dr Hidenori Akutsu became interested in nuclear reprogramming in mammalian species when he was a research fellow at University of Hawaii under Dr Ryuzo Yanagimachi. This interest endured and motivated him to undertake further research for epigenetic and nuclear reprogramming under Dr Minoru Ko at NIA/NIH and Dr Kevin Eggan at Harvard University.
While at Harvard University he also became an important part of Dr Douglas Melton's team, deriving human embryonic stem cell lines which were later offered freely to the scientific community to facilitate the efforts of other scientists. His special interests are deriving human embryonic stem cells for applying to clinical use, and egg development and epigenetic reprogramming.
|
|
|
|
|
 |
| Mr. B N Manohar
CEO Stempeutics Research Pvt. Ltd, Bangalore |
Manohar has been associated with the Manipal Group since Jan 2002 and has taken up the role of President at Stempeutics in August 2007. Prior to this Manohar has handled multiple assignments in the Group – starting Manipal Infocom a BPO Organization and successfully migrating it to Manipl–Omega Healthcare BPO JV, taking over a start up Distance Education business and growing it to Rs 70 Crores, starting a CPO business with WIPRO, establishing and propping up the new Education Services business consisting of On Line Assessment & Testing business, Vocational Education business, Engineering Twinning Education Program and E-content development.
Prior to Joining Manipal Group, Manohar has had long and successful stints at Wipro GE Medical Systems. Manohar has a rich domain expertise in strategy planning for various industry segments, Business Development, Process Re-engineering, Business System integration and leveraging IT Technology for service operations.
Manohar has done his B.E. from Regional Engineering College, Trichy and M.E. from Guindy Engineering College, Chennai.
|
| |
|
|
|
|
 |
| Dr. Anish Sen Majumdar, Chief Scientific Officer
Stemeputics Research Pvt. Ltd. |
|
Anish Sen Majumdar is currently the Chief Scientific Officer of Stempeutics Research Pvt. Ltd., India, and has been working in the field of stem cell research and therapy for more than 15 years. Dr. Majumdar received his Ph.D. in Biochemistry from the University of Calcutta.
He pursued post doctoral research at the University of Pennsylvania and subsequently joined Stanford University School of Medicine in California as a Research Scientist. Dr. Majumdar has worked for both international and Indian biopharmaceutical companies in different capacities, including Geron Corporation, California, USA as Senior Director of Cell Therapy Research, and later at Reliance Life Sciences, Navi Mumbai as Vice President of Stem Cell Research in Regenerative Medicine. Dr. Majumdar has published more than 50 research articles in international peer-reviewed journals and a co-inventor in 10 patents.
He has been nominated as a member of the Industry Committee of the International Society of Stem Cell Research (ISSCR) in 2011.
|
|
|
|
|
 |
| Dr. Deepa Ghosh, M.Pharm.,PhD. |
| Group Head,
Tissue Engineering Dept.,
Reliance Life Sciences Pvt. Ltd.
DALC- Life Sciences Center
R-282, TTC Area of MIDC,
Thane Belapur Road,
|
Expertise: Tissue Engineering & Wound management
Education: PhD (Pharmacology): Uniformed Services University of the Health Sciences (USUHS), MD, USA (1992-1996)
Master of Pharmacy: Birla Institute of Technology and Science (BITS), Pilani, India. (1990-91)
Bachelor of Pharmacy: Madras University, India. (1985-1989)
Professional Experience: Group Head, Tissue Engineering Group- Reliance Life Sciences (2005-date)
Research Scientist- Tissue Engineering Group- Reliance Life Sciences (2001-2005)
Principal Scientist- Glenmark Pharma, Mumbai (1999-2000)
Post-Doctoral Fellow: Emory University, Atlanta, USA (1996-1998)
Research Achievements: Developed four cell therapy products which are currently at various stages of clinical trials.
Developed novel wound dressings. Products are currently marketed.
Received SBIRI-DBT funding for conducting clinical trials on a tissue engineered product for addressing cartilage damage.
IPR: Patents: 6 Publications in International peer-reviewed Journals: 15
|
|
|
|
|
|
|
 |
| Prof Geeta K Vemuganti,
MD, DNB, FAMS, FICP |
| Dean, School of Medical Sciences University of Hyderabad |
A physician- pathologist by training, with special interest and experience in ocular pathology and stem cell research.
Ocular Pathology: Areas of interest include in corneal infections, genotype-phenotype correlation in corneal dystrophies, oculo-adenexal tumors; especially retinoblastoma, ocular surface squamous cell carcinoma.
Stem cell research: Translational research, specially related to ocular surface reconstruction using cultivated epithelial sheets using human amniotic membrane as a carrier. Current research interests; Plasticity of Bone marrow stromal cells; Biology of limbal, conjunctival and oral mucosal cells; and cancer stem cells in ocular tumors.
|
|
|
|
 |
| Dr. Maryam Kabir-Salmani,
Ph.D., |
| Assistant professor, Dept. Molecular Genetics National Institute of Genetic Engineering and Biotechnology. |
|
|
|
|
 |
| Dr. Lukas Utiger, |
| Chief Operating Officer and vice president of Bioscience Division at Lonza, USA. |
Lukas Utiger has been Chief Operating Officer and vice president of Bioscience Division at Lonza Group AG since June 2010.
Dr. Utiger served as Chief Operating Officer of Life Science ingredients Division of Lonza Group AG since August 1, 2006. Dr. Lukas served as a Head of Exclusive Synthesis Business Sector of Lonza Group AG since August 2001. He has been a Member of the Management Committee of Lonza Group AG since August 2001. He served as a Head of Research and Development for Exclusive Synthesis for Lonza Group from October 2000 to July 2001.
He Joined Lonza as R&D chemist in 1992 and became R&D group leader for fine chemicals in 1998; Acquired his business experience at ICI Chemicals & Polymers Division in Runcorn from 1988 to 1992.
He holds a PhD in chemical engineering from Imperial College, London.
|
|
|
|
 |
| Dr. Olexander L. Kukharchuk Director EmProCell Clinical Research Navi Mumbai, India |
|
Dr. Olexander L. Kukharchuk was specialized as "medical practioner" at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). CMSc. (Candidate of Medical Science) defended on 1989 in the session of specialized academy council at Kaunaski Medical Institute (Lithuania). D.M.Sc (Doctor of Medical Science) defended 1996 in the session of specialized academic council at Odessa Governmental Medical University (Ukraine).
Associate Professor obtained on 1996, Professor obtained on 2001. 1982-1991: Assistant, Department of Pathophysiology Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). 1991-1994: Senior Tutor, Normal Physiology with course of Pathophysiology at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). Head of the Central Research Laboratory and Senior Tutor of the Pathophysiology Department at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). 1994-1995: Head of Central Research Laboratory, Associate Professor of the Normal Physiology Department at Bucovinian Government Medical Academy (Ukraine, Chernivtsi).
1995-1997: Director of the Centre for Scientific-Medical Investigation at Bucovinian Government Medical Academy (Ukraine, Chernivtsi). 1997-2002: Head of the Normal Physiology Department at Bucovinian Government Medical University (Ukraine, Chernivtsi). 2002-2005: Research Director of the Centre for Embryonic Cells "EmCell"(Ukraine, Kiev). 2005-2006: Research Director of the Coordination Centre for Transplantation of Organs, Tissues and Cells of the Ukraine Health Ministry (Ukraine, Kiev). 2006-2010: Director of Coordination Centre for Transplantation of Organs, Tissues and Cells of the Ukraine Health Ministry; Chief Specialist of the Ukraine Health Ministry by specialization "Transplantology"; Research Director of Institute of Cell Therapy (Ukraine, Kiev); Director EmProCell Clinical Research Pvt. Ltd. (India, Mumbai).
Dr. Olexander L. Kukharchuk is editor of the Journal "Transplantology". He is also well known for his work in the study field of immunological aspects of stem cell transplantion and aging theory-depletion of stem space. He is author of 14 patents, 238 scientific publications.
Dr. Olexander L. Kukharchuk guided clinical trials for evaluation of fetal progenitor cells transplantation efficacy in diabetes mellitus, chronic lower limb ischemia, myocardiodystrophy, liver cirrhosis, male infertility, aging, pancreonecrosis, glomerulonephritis, rhemutoid arthritis, lupus erythematosus. He is author of the book "Stem cells: Experiment, Theory, Clinic. Embryonic, mesenchymal, neural, hematopoetic stem cells".
Dr. Olexander L. Kukharchuk guide for fundamental and applied scientific research of Health Ministry Ukraine: "Study the growth factors interrelating central and peripheral regulatory mechanism of immunological reactivity and hemocoagulatory potential in the normal, endo- and exogenous intoxication", "Determine the criteria of efficacy and safety of transplanting organs, tissues, cells and develop its standards", "In experiments and clinicals, to determine effectiveness of transplantation of stem cells, tissues of embryo and exofetal material and tissue therapy by Filatov in immune and oncopathological process, pancreo- and colonogenic peritonitis, aging and dysfunction of reproductive system".
|
|
|
|
|
 |
| Dr. Geeta Jotwani Assistant Director General
Indian Council Medical Research Division of Basic Medical Sciences, New Delhi.
|
|
Ph D from All India Institute of Medical Sciences, New Delhi. Trained for Bioethics and Ethics Committee Administration at WHO, NIH and University of Washington certified Western Institutional Review Board, Olympia, Washington, USA
17 years in the field of Clinical Biochemistry, Developmental Neurobiology and Genomics of Brain Tumors. Since 2001 in administration of medical research at Apex advisory body under Ministry of Health & Family Welfare.
Currently assigned the duties and responsibilities at the Indian Council of Medical Research, headquarters to co-ordinate various activities related to emerging areas of biomedical research including Genomics and Molecular Medicine & Stem Cell Research, GM Food Safety Assessment and also coordinating new emerging areas of medical sciences like Nano-medicine, Pharmaco-genomics
Initiated activities in Stem Cell Research and Therapy which includes co-ordination of all major activities on basic and applied research in the area of Stem Cell Research and also the clinical trial application received by the council. Instrumental in drafting Guidelines for Stem cell Research & Therapy (2007). ICMR representative on few ICSCRTs of the institutions.
Foods Derived from Genetically Modified (GM) Crops involved in capacity building programme for foods derived from genetically modified crops, which includes organizing workshops and International Conferences. Also involved in preparation of Guidelines for Safety assessment of GM Food including issues related to Biotechnology; Safety and testing methodologies; Labelling; Nutritional; and Ethical and public awareness.
Membership of Professional Societies/institutions
- Member/ICMR Nominee on National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT)
- Board Member of Western Institutional Review Board, Olympia, Washington, USA
- Executive member of Stem Cell Research Forum of India (SCRFI)
- Alternative member of Biotechnology for Food and Agriculture Sectional Committee, FAD 23, Bureau of Indian Standards, Manak Bhavan, New Delhi
- Member for DST Task Force for Drafting Regulatory Framework for Nanotechnology in India
- Member of the TF on Implementation of Nanotoxicity, BIRAP, DBT
- Member of the TF on implementation of Guidelines on Disaster Management of Biological NDMA
|
|
|
|
|
 |
| Dr. Ramesh Bhonde Professor & Dean,
Manipal Institute of Regenerative Medicine, Bangalore, India |
|
Dr. Ramesh Bhonde is a Professor & Dean, at the Manipal Institute of Regenerative Medicine, Bangalore. He superannuated from National Center for Cell Science Pune as Scientist ‘F’ and joined Stempeutics Research Pvt. Ltd. Bangalore as Technical Director and then moved to Stempeutics Research Malaysia branch in Kuala Lumpur, Malaysia. He has been working in the field of pancreatic regeneration in diabetes for the past twenty years. His areas of interest and expertise include Stem cells, Regenerative Biology, Tissue banking and engineering with special reference to the cultivation of fastidious cells such as hepatocytes, vascular endothelial cells, islets of Langerhans,. He has extensively worked on in vitro generation of islets from pancreatic and non- pancreatic stem cells.
He demonstrated that mesenchymal stem cells derived from human umbilical cord, placenta, amnion and adipose tissue are capable of differentiating into functional islets. These in vitro generated islets could reverse experimental diabetes in mice upon transplantation. He also showed that multiple injections of unfractionated bone marrow reverses experimental diabetes in mice .His pioneering work on stem cells in breast milk is well appreciated by scientific community. He has guided till now 16 Ph. D students. He has more than 150 publications, 3 book chapters and 3 patents to his credit.
|
|
|
|
|
 |
| Dr. Aroop Kumar Dutta, |
| Managing Director of ExCel Matrix Biological Devices P. Ltd. |
Dr. Aroop Kumar Dutta is the Managing Director of ExCel Matrix Biological Devices P. Ltd. Dr. Dutta is a biochemical engineer by profession with master of technology and PhD degrees form Indian Institute of Technology, Kharagpur. After working with some leading generic biopharmaceutical players in India he decided to follow his heart to pursue innovative R&D as regenerative medicine start up.
ExCel Matrix, a start-up company, has vision to develop innovative 3D cell culture technologies for regenerative medicine and strategies to commercialize such technologies. Company's flagship ECM Analog and Sol-Cell-Gel technologies have been acknowledged by experts and won several innovation awards. Product development activities of ExCel Matrix are financially supported by Department of Biotechnology (DBT) and Department of Scientific and Industrial Research (DSIR) under innovation support schemes.
Dr. Dutta is passionate about fusing biology with engineering for practical healthcare solutions. His greatest dream is to build a "Skunk Works" team in bioengineering and regenerative medicine.
|
|
|
|
|
 |
| Dr.Philip G. Vanek,
PhD. |
| Head of Innovation, Lonza Bioscience, USA |
Dr. Vanek joined Lonza as Head of Business Development, Cell Therapy in October of 2007. In this capacity, he has worked with many emerging-stage therapeutic companies to help support their development of scalable commercialization strategies. He currently serves as the Head of Innovation for Lonza's Bioscience Sector and sits on the Global Innovation Strategy Team for Lonza Group.
Prior to joining Lonza, Phil was Director of Global Marketing for BD Biosciences' Bioimaging Systems group formed following the acquisition of Atto Bioscience by Becton Dickinson in July of 2004. At Atto, he was Director of Corporate Development responsible for product commercialization and business development. Prior to joining Atto Bioscience in 2001, Phil directed the Functional Genomics and Proteomics business unit at Life Technologies (Gibco/BRL).
Phil received his Ph.D. in Biochemistry from Georgetown University Medical Center in Washington, DC, and subsequently held an IRTA fellowship at the National Cancer Institute in the Laboratory of Molecular Oncology directed by Dr. Takis Papas. He continued his post-doctoral training at the Hollings Cancer Center at the Medical University of South Carolina in Charleston, in the Center for Molecular and Structural Biology.
Phil is an instructor for Johns Hopkins University Advanced Academic Programs and has lectured at Georgetown University School of Medicine in the Masters of Biotechnology Program. He has also chaired sessions for a number of local and international meetings in biotechnology.
|
|
|
| Details of other reknowned speakers will be updated regularly |
|
|
|
|
|
|
 |
|
 |
|
|
| Supported By: |
 |
|
|
|
|
